John Paul II Hospital, Krakow, Poland.
Clin Chem Lab Med. 2012 Oct 1;50(10):1825-31. doi: 10.1515/cclm-2012-0015.
BACKGROUND: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inflammatory mediator involved in atherosclerosis. Since aortic valve stenosis (AVS) is regarded as an atherosclerosis-like inflammatory disease, we sought to investigate whether AVS is associated with elevated Lp-PLA2. METHODS: Plasma Lp-PLA2 levels were determined in 48 consecutive patients with severe AVS without atherosclerotic vascular disease and compared with the values obtained in 48 controls matched for age, sex and cardiovascular risk factors. RESULTS: Lp-PLA2 was higher in AVS than in controls (242.3±50.4 vs. 151.9±28.1 ng/mL, p<0.0001). Lp-PLA2 correlated inversely with aortic valve area (AVA) (r=-0.53; p=0.0001) and positively with mean pressure gradient (PG) (r=0.32; p=0.029). In multivariable analysis C-reactive protein (CRP) (OR=1.42; 95% CI 0.95-2.1; p=0.09) and AVA (OR=0.003; 95% CI 0.00004-0.23; p<0.01) were independently associated with Lp-PLA2 above a mean of 242 ng/mL. After adjustment for CRP, AVA was the only independent predictor of Lp-PLA2 in AVS patients (p<0.001). CONCLUSIONS: This study is the first to show that AVS is characterized by increased plasma Lp-PLA2 levels associated with the severity of AVS, which suggests active involvement of Lp-PLA2 in the pathogenesis of AVS.
背景:脂蛋白相关磷脂酶 A2(Lp-PLA2)是一种参与动脉粥样硬化的炎症介质。由于主动脉瓣狭窄(AVS)被认为是一种类似动脉粥样硬化的炎症性疾病,我们试图研究 AVS 是否与升高的 Lp-PLA2 相关。
方法:在 48 例无动脉粥样硬化性血管疾病的严重 AVS 患者中测定血浆 Lp-PLA2 水平,并与年龄、性别和心血管危险因素相匹配的 48 例对照者的数值进行比较。
结果:AVS 患者的 Lp-PLA2 高于对照组(242.3±50.4 比 151.9±28.1ng/mL,p<0.0001)。Lp-PLA2 与主动脉瓣面积(AVA)呈负相关(r=-0.53;p=0.0001),与平均压力梯度(PG)呈正相关(r=0.32;p=0.029)。多变量分析显示,C 反应蛋白(CRP)(OR=1.42;95%CI 0.95-2.1;p=0.09)和 AVA(OR=0.003;95%CI 0.00004-0.23;p<0.01)与 Lp-PLA2 平均值以上 242ng/mL 独立相关。在调整 CRP 后,AVA 是 AVS 患者 Lp-PLA2 的唯一独立预测因子(p<0.001)。
结论:这项研究首次表明,AVS 的特征是血浆 Lp-PLA2 水平升高,与 AVS 的严重程度相关,这表明 Lp-PLA2 积极参与 AVS 的发病机制。
JACC Cardiovasc Imaging. 2014-11-1
Acta Med Croatica. 2010-10
Eur J Clin Invest. 2013-11-28
Int J Cardiol Heart Vasc. 2024-10-30
Front Cell Dev Biol. 2022-1-27
Int J Clin Exp Med. 2015-12-15